ANI Pharmaceuticals (NASDAQ:ANIP) Rating Lowered to “Sell” at StockNews.com

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday.

A number of other research firms also recently issued reports on ANIP. Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Truist Financial lifted their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock traded down $1.30 on Tuesday, hitting $59.12. The company’s stock had a trading volume of 91,181 shares, compared to its average volume of 182,069. The company has a fifty day moving average price of $56.42 and a 200-day moving average price of $58.62. The firm has a market cap of $1.24 billion, a P/E ratio of -107.49 and a beta of 0.73. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same period last year, the firm posted $1.05 EPS. The business’s revenue was up 12.5% on a year-over-year basis. On average, equities analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,381 shares of company stock worth $2,441,556. Company insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in the company. abrdn plc purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth approximately $13,155,000. China Universal Asset Management Co. Ltd. grew its holdings in ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after acquiring an additional 412 shares in the last quarter. BTC Capital Management Inc. lifted its holdings in ANI Pharmaceuticals by 12.4% during the fourth quarter. BTC Capital Management Inc. now owns 10,623 shares of the specialty pharmaceutical company’s stock worth $587,000 after buying an additional 1,172 shares during the period. KBC Group NV raised its holdings in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after acquiring an additional 310 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.